Alkem Labs posts highest-ever EBITDA in FY26; Q4 revenue rises 14.6%
Strong domestic and international growth, improving product mix, and operational efficiencies drive margin expansion despite exceptional charges impacting quarterly profit
Strong domestic and international growth, improving product mix, and operational efficiencies drive margin expansion despite exceptional charges impacting quarterly profit
With robust FY26 growth, plans AI-led diagnostics and genomic testing expansion
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
The pharmaceutical segment led growth, generating Rs. 337 crore in revenue, while the crop protection business contributed Rs. 157 crore
The company reported profit before tax of Rs.67 crore, up sharply from Rs.21 crore in the same period last year
Profitability metrics showed a sharper upward trend. Gross margin expanded 280 basis points to 61.2%
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
Newly commissioned MCC in Jhagadia and Dahej and CCS project expansions will unlock an additional 8,800 MTPA, fuelling year-over-year revenue gains of 20%-30% in excipients
Good momentum in commercial CDMO business
Subscribe To Our Newsletter & Stay Updated